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Abstract
Follicle-stimulating hormone (FSH) and luteinizing hormone (LH) play essential roles in 
animal reproduction. They exert their function through binding to their cognate receptors, 
which belong to the large family of G protein-coupled receptors (GPCRs). This recognition at 
the plasma membrane triggers a plethora of cellular events, whose processing and 
integration ultimately lead to an adapted biological response. Understanding the nature and 
the kinetics of these events is essential for innovative approaches in drug discovery. The 
study and manipulation of such complex systems requires the use of computational 
modeling approaches combined with robust in vitro functional assays for calibration and 
validation. Modeling brings a detailed understanding of the system and can also be used to 
understand why existing drugs do not work as well as expected, and how to design more 
efficient ones.
Introduction
Follicle-stimulating hormone and luteinizing hormone receptors (FSHR and LHR) play central 
roles in animal reproduction. These two receptors belonging to the family of G protein-
coupled receptors (GPCRs) are able to transduce the signals mediated by the variations of 
FSH and LH blood concentrations in adapted cellular responses in gonads, mostly through 
the control of follicle development in the ovary and gametogenesis in the testis (Ascoli et al.,
2002; Simoni et al., 1997). Binding of the hormone to its cognate receptor triggers cascades 
of biochemical reactions within the cell, which results in profound changes in gene 
transcription (Friedmann et al., 2005) and protein translation (León et al., 2014; Musnier et 
al., 2012). These signaling cascades mainly originate from the interaction of the activated 
receptors with G proteins  on the one hand, and ß-arrestins on the other hand (Gloaguen et 
al., 2011; Landomiel et al., 2014; Ulloa-Aguirre et al., 2011). The precise balance between 
these two pathways is essential for the biological outcome of cell stimulation. As an 
example, the modification of this balance in the N680S single nucleotide polymorphism in 
the FSHR is thought to be responsible for the relative resistance of S/S women to FSH 
treatments (Tranchant et al., 2012).
GPCRs being membrane receptors have a high specificity for their ligands, and are often 
individually expressed in a reduced number of cell types. Moreover, they are involved in 
most cellular processes. Consequently, they are ideal drug targets being the target of about 
40% of marketed drugs (Ma and Zemmel, 2002). Some of these drugs are balanced full 
agonists, meaning that they trigger the same signaling pathways than the natural agonists, 
with the same balance between G-dependent and ß-arrestin-dependent pathways. During 
the last decade, it has been shown that it was possible to find GPCR ligands, generally 
referred to as “biased”, which trigger only part of the natural ligand’s signaling repertoire. 
From the therapeutic point of view, such pharmacological profile are thought to be more 
efficient and safer since only the beneficial pathways (G proteins or ß-arrestins) are targeted.
The most famous example of such use of GPCR biased ligand is carvedilol (Wisler et al., 
2007), one of the ß-blockers used in heart failure pathologies. By blocking the ß-adrenergic 
receptor, they reduce the catecholamine stimulation in heart and other organs. Contrarily to
most ß-blockers which are full antagonists, carvedilol only blocks the G-dependent 
pathways, leading to therapeutic efficacy comparable to the one of other ß-blockers, but it 
extends survival (Poole-Wilson et al., 2003). 
Although the events following ligand binding are referred to as signaling pathways, the term 
of signaling networks better represents the complexity of these events and the tight 
interconnections between them. This complexity can be envisaged at different levels. (1) A 
large number of molecules participate to this network, and there are many regulation 
feedback loops within it. (2) The existence of homo- and hetero-dimers has been 
demonstrated for many GPCRs (Parmentier, 2015) (je citerai ma revue dans Annu Rev Pharm
Toxico). (3) The biological outcome depends on the duration of the stimulation and on the 
stimulation profile (short vs long, continuous vs pulsatile). (4) In vivo the cell is submitted to 
multiple and coordinated stimulations, and the resulting signaling networks are interlocked. 
Those points are nicely illustrated by the strong interconnections between LH and FSH, 
which (1) share large portions of intracellular mechanisms triggered by their cognate 
receptors (Figure 1), (2) whose receptors have been shown to heterodimerize (Mazurkiewicz
et al., 2015), (3) have very precise and coordinated profiles,-and antagonistic cellular effects, 
(4) and of course both are involved in the control of reproduction.
The pharmacology of gonadotropin receptors is still very poor as only natural hormones are 
used, either extractive in animal reproduction, or recombinant in human health. These last 
years have seen the appearance of many small molecules (Nataraja et al., 2015), either 
targeting the orthosteric site (as the natural ligand), or allosteric modulators (modulating the
action of the natural ligand) of the FSHR and LHR (+ Dias.J et al, MCE 2011). However, 
optimizing the action of such pharmacological molecules requires the detailed knowledge of 
their action, which in turn depends on the precise knowledge of the signaling networks. Over
the last decade it has became increasingly evident that computational modeling is a tool of 
choice for such purpose.
Modeling the signaling network activation
Signaling networks trigger complex cellular responses such as proliferation, differentiation, 
apoptosis, through the regulation of transcription and translation processes. Each of these 
responses results from precise kinetic activation/deactivation profiles of the molecules 
constituting the network. Therefore, it is of paramount importance to understand the major 
molecular mechanisms set off by the binding of a given ligand to the receptor, how this 
signal propagates throughout the signaling network, and how the different profiles are 
integrated in adapted cellular responses. The complexity of these networks in itself prohibits
the direct measurement of all the kinetic profiles. Moreover, for many of these molecules, 
the tools are not available. Building computational kinetic models of the network allows 
accessing these profiles by measuring only a small subset or readouts.
Two main types of models should be distinguished: topological (or static) models, which list 
the molecules belonging to the network and the relations between them (activation, 
inhibition, phosphorylation, etc.); and dynamic models, which describe the precise kinetic 
evolution of the molecule concentrations.
Topological models are a necessary first step in any modeling process. Indeed, building the 
model entails a detailed study of the literature, and addresses questions that would 
otherwise remain unresolved. This model can also be used to answer qualitatively to the 
question “can my data be obtained with this model?”. At first try the answer is usually 
negative, and iterations between modeling and experimental results are always necessary 
before a satisfying model is found. We have done this work for the FSH model (Gloaguen et 
al., 2011), and it involved the analysis of more than 150 papers, from which more than 200 
experiments were extracted and used for building the model. Figure 1 shows a schematic 
view of this model.
GPCR-induced signaling events involve fast and reversible reactions. Consequently, static 
models cannot faithfully represent the outcome of receptor activation. Moreover, the time-
scale of the different pathways is often different, and some molecules have a clear biphasic 
profile. The best known example is the bimodal phosphorylation of ERK, which occurs in 
seconds through the G-dependent pathway, but lasts only a few minutes, then after 10 
minutes depends on the ß-arrestin dependent pathway, and extends beyond an hour. Static 
models cannot represent such biphasic behavior. Even worse is the case of cAMP since the 
production of cAMP is activated by the Gαs pathway, but inhibited by the ß-arrestin pathway
upon the activation of a given receptor.
It is therefore fundamentally important to take dynamics into consideration when trying to 
model and predict the outcome of receptor activation. The ordinary differential equations 
(ODE) formalism is the most popular for dynamic models. In this formalism, the 
concentration variation of a given molecule is expressed as a function of time, and depends 
on concentrations of the other molecules within the network. Different rate laws for the 
reactions within the network can be chosen. The simplest kinetic law is derived from the law 
of mass action (Figure 2A and B). This model is built from the static model, adding kinetic 
constants on the reactions and initial concentrations of the different molecules.
Estimating parameters to predict biological responses
The major problem at this point  is that these constants and concentration are usually 
unknown, and for most of them not accessible. However, computational methods exist to 
estimate these parameters from a limited number of experimental data. The principle of 
parameter estimation is to search for sets of values that, when used to simulate the model 
dynamics, reproduce experimental data (Figure 2C and D). We have developed such a 
method, and applied it to the modeling of the angiontensin signaling pathway (Heitzler et al.,
2012). We have shown that when the simulation tightly fits experimental data, it is possible 
to predict the behavior of the system in biological conditions different from those used to 
acquire initial data. For example, the opposite effects of ß-arrestins 1 and 2 on the 
phosphorylation of ERK (by inhibiting or activating, respectively) is correctly predicted. 
Moreover, the predicted dose-responses of ERK phosphorylation in control conditions and 
when ß-arrestin 1 or ß-arrestin 2 are depleted are very close to the measured ones (Figure 
3).
From this model we were able to propose hypotheses that were then validated 
experimentally. For example, the model predicted that the desensitization pathway exerts a 
strong inhibition on the ß-arrestin-dependent signaling pathway. This hypothesis has been 
validated in HEK293 cells, but also in primary vascular smooth muscle cells, which naturally 
express the angiotensin II (AT1) receptor. We were also able to show that this mechanism 
exists for other GPCRs, including the FSHR. 
Obtaining experimental data to build models
Because the calibration of the model is made through fitting experimental data, the quality 
of the final model is tightly linked to the quality of these data. Until recently, the method of 
choice for following the kinetics of signaling events has been the measurement of 
phosphorylation in Western blot assays at different time points. However, this method has 
many drawbacks in terms of computational modeling. First, the different time points 
correspond to different cell cultures. Even if the biological conditions are very tightly 
controlled, there will always be some minor differences between the different wells. Second,
it cannot be envisaged to acquire data at very close time points and on a long period. 
Consequently, there are multiple solutions for drawing a curve that passes through all the 
experimental point (Figure 4A).
In that regard, newly developed methods based on fluorescence and luminescence energy 
transfer allowing measuring cellular events in living cells are very precious. Indeed, they 
allow to acquire the complete kinetic profile on the same cells, and to have a very short 
interval between time points, guarantying uniqueness of the solution (Figure 4B). 
Such assays have been developed and were recently applied to the study of FSHR and LHR 
signaling networks (Ayoub et al., 2015). Using bioluminescence and fluorescence resonance 
energy transfer (BRET and FRET), we were able to measure the activation of heterotrimeric G
protein, production of cAMP, calcium release, ß-arrestin 2 recruitment and receptor 
internalization and recycling in real-time and live cells (Figure 5). By measuring kinetic 
profiles at different hormone concentrations, it is also possible to obtain dose-response 
curves for each pathway (Figure 6). Such an analysis led to interesting observations in terms 
of how can the different pathways triggered by a given recepotor be regulated. Indeed, it 
appears that there is a 3 log difference in sensitivity to ligand concentration between the G-
dependent and ß-arrestin-dependent pathways, which is very unusual for GPCRs. Now 
remains the task of understanding the role of this difference in the physiology of gonadal 
cells.
Affinity, efficacy and potency 
Receptor-ligand interactions are classically characterized by two essential parameters: i) 
affinity, which reflects the energy of the ligand-receptor interaction and ii) intrinsic efficacy, 
which measures a biological response to ligand binding. The combination of these two 
parameters defines the potency (Figure 7A). Consequently, two ligands having different 
affinities can exhibit the same potency if the less affine ligand has better intrinsic efficacy. 
This point is very important in the context of drug screening, since the affinity is not 
necessarily the best indicator of a good lead. 
However, in the case of GPCRs, and probably for other types of membrane receptors, this 
model is an oversimplification. Indeed, the classical determination of intrinsic efficacy relies 
on the hypothesis of a single, linear signaling pathway going from the receptor to the 
measured biological outcome (Figure 7A). However, the efficacy should take into account at 
least G-dependent and ß-arrestin-dependent signaling (Figure 7B). These two pathways are 
the most proximal events in the signaling network and difficult to measure. Therefore, more 
distant outcomes are often chosen, such as cAMP production for the Gs-dependent pathway
and ERK and PDE for ß-arrestin which also affect cAMP levels. Consequently, cAMP levels do 
not accurately reflects Gs activation, and efficacy and potency cannot be derived 
straightforwardly from it (Figure 7C).
Consequently, ligand bias, although its mere existence is not questioned any longer, is 
difficult to evaluate. The idea is to be able to compare the efficacies related to two different 
effectors, for different ligands. For example, in the case of the FSHR, a ligand biased towards 
the ß-arrestin pathway would be a ligand eliciting more ß-arrestin activation, relative to Gs,
than the natural ligand (Figure 7D). Different methods have been proposed for computing 
this bias (Kenakin, 2014; Landomiel et al., 2014; Rajagopal et al., 2011). All these methods 
have in common to be derived from Black & Leff’s operational model (Black and Leff, 1983), 
which gives a simple mass-action based model to fit  the measurement of dose-responses. 
As already mentioned for efficacy and potency, in practice this requires the measurement of 
effectors immediately downstream the receptor at different ligand concentrations. When 
more distant downstream read-outs are chosen, the distortions introduced in the kinetics of 
activation by the presence of intermediaries and/or cross-talks renders the calculation 
mathematically challenging.
By allowing simulating kinetic profiles that are not easily accessible to experimentation, 
computational modeling can help solve this question. For example, in the angiotensin II 
signaling network published in (Heitzler et al., 2012), although only DAG, active PKC and 
phosphorylated ERK were measured experimentally, G activation and ß-arrestin recruitment 
could be simulated (Figure 8). We were able to partially validate these simulations by the 
computation of activation half-lives (3.3s for G and 80s for FSHR-ß-arrestin 2) and the 
comparison with measured values in independent publications (0.3-2s for G (Lohse et al., 
2008; Vilardaga, 2010) and 20-50s for FSHR-ß-arrestin 2 (Lohse et al., 2008; Rajagopal et al., 
2006)). 
Conclusions
Methods now exist to model signaling networks. The quality of these models tightly depends
on the quality of the experimental data used to calibrate them. In that regard, luminescence 
and fluorescence-based assays provide irreplaceable constraints for the estimation of 
unknown parameters. As shown through the angiotensin receptor model, such models allow
predicting the behavior of the system in biological conditions different from those used to 
acquire calibration data. It is thus possible to choose the most interesting conditions, and 
implement high added-value experiments. Models can also be used to better understand the
effects of biased ligands, and consequently pave the way to a better method for estimating 
biases, but also for understanding how they affect the biological outcome they induce, 
thereby participating in the development of better drugs, more efficient and safer.
 
Figure legends
Figure 1:  Schematic view of the FHSR and LHR signaling networks.
Figure 2: (A) For any chemical reaction, the variation d[B] of the concentration of B in the 
short time dt can be written as a function of the concentrations of A and B and the rate 
constants k0 and k1 (equation 1). In the case of the mass action law, this function takes the 
form indicated in equation 2. (B) When the reaction is catalyzed by molecule C, this function 
takes the form indicated in equation 3. (C) The dynamic network is built from the static 
network by adding kinetic rates on reactions and considering the initial molecules 
concentrations. (D) The error between the experimental values and a simulation, obtained 
using a given set of parameter values, is a function of the differences between measured and
simulated points. (E) To estimate the values of the unknown parameters an iterative method
is used at each step, on or more sets of parameter values are simulated, and the 
corresponding error computed. If the error is not null, the values of parameters are 
modified. This iterative process stops when the error is null or when the maximal number of 
iterations is reached.
Figure 3: Comparison of simulated and measured dose-responses of ERK phosphorylation 
triggered by the angiotensin receptor in control conditions, and conditions depleted in either
ß-arrestin 1 or ß-arrestin 2.
Figure 4: Data obtained through classical Western blot analysis (A) do not introduce a lot of 
constraints to the model, and many different curves passing through all the experimental 
points can be drawn. On the contrary, with FRET/BRET data (B), the curves going through all 
the data points are close to each other.
Figure 5: Different BRET assays for the study of FSHR and LHR signaling networks. (A) 
CAMYEL assay for measuring the kinetics of cAMP production. In the basal state the Rluc and
GFP fused to Epac are close to each other, allowing an important energy transfer. When the 
receptor is activated, cAMP is produced and binds to Epac changing the conformation of 
Epac and increasing the distance between Rluc and GFP which is measured as a BRET 
decrease. n=3 for FSHR and LHR. (B) Assessment of G activation. At the basal state, the ,  
and  subunits of the heterotrimeric G-protein are in complex, bringing close together the 
Rluc fused to G and the Venus fused to G, allowing an important energy transfer. When 
the receptor is activated and the G is activated, thus dissociating from G, the distance 
between Rluc and Venus increases and consequently the BRET signal decreases. n=2 for 
FSHR, n=1 for LHR (C) Measurement of calcium release. In absence of calcium, aequorin is 
inactive and not able to transfer energy to GFP. When the receptor is activated and calcium 
is released, aequorin conformation changes and transfers energy to GFP. n=2 for FSHR, n=3 
for LHR. (D) Measurement of ß-arrestin 2 recruitment. At the basal state the Rluc fused to 
the receptor and the yPET fused to ß-arrestin 2 are too distant for energy transfer. 
Recruitment of the ß-arrestin 2 to the receptor after activation brings them closely together 
and the BRET signal increases. n=2 for FSHR and LHR.
Figure 6: Dose-response analysis on cAMP production and ß-arrestin 2 recruitment for 
hFSHR (left) and hLHR (right), the individual dose-response data obtained in each BRET assay
as indicated were normalized to the maximal signal taken as 100% of receptor-mediated 
responses. 
Figure 7: Measuring affinity, efficacy and potency. In the classical paradigm (A), the affinity is
measured by the dissociation constant Kd. To evaluate the potency and efficacy, the 
quantity of effector is measured as a function of ligand concentration.  The potency (Emax) is
the maximal response that can be obtained, and efficacy (EC50) is the ligand concentration 
necessary to obtain half of the maximal response. In a more complex case (B), efficacies and 
potencies relative to different effectors could still be defined. If effectors are not direct 
targets of the receptor and intermediary molecules exist between them, or if one effector 
affects the other one, efficacies and potencies cannot be defined.
Figure 8: Simulations of the kinetic profiles of active G protein and FSHR-ß-arrestin 2 
signaling complex in the angiotensin signaling network.
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